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Abstract
Background: Branch retinal vein occlusion (BRVO) commonly occurs at the arteriovenous crossing in the unilateral
eye, and cardiovascular diseases can be risk factors of BRVO. However, the pathomechanism leading to BRVO is not
yet clear. In addition to mechanical compression, the vein might locally constrict due to an altered biochemical
environment, such as an increase in the concentration of endothelin-1 (ET-1). We evaluated changes in ET-1
following injection of intravitreal bevacizumab (IVB), which is the anti-vascular endothelial growth factor (VEGF)
agent with the longest serum half-life, to determine the effect on BRVO-related macular edema.
Methods: Twenty consecutive patients with BRVO-related macular edema (10 males, 10 females; age range
56–83 years) who visited our hospital were included in this prospective study. Visual acuity (VA); central retinal
thickness (CRT), determined by macular optical coherence tomography (OCT); and plasma ET-1 levels were obtained
before IVB treatment and 1 month later.
Results: Patients had hypertension (80 %), dyslipidemia (50 %), diabetes mellitus (35 %), or collagen disease (5 %).
Mean CRT was significantly decreased from 673.0 ± 327.8 to 388.2 ± 155.0 μm (P = 0.0007), and mean VA was
significantly improved after IVB (P = 0.0239). Mean plasma ET-1 was significantly decreased from 1.272 ± 0.451 to 1.
095 ± 0.316 pg/mL (P = 0.0238); however, the plasma ET-1 level was increased in all five patients who did not show
improved VA after IVB.
Conclusions: In patients with BRVO-related macular edema, anti-VEGF therapy leads to an expected reduction in
ET-1 levels; however, the ET-1 level was found to increase in some patients; this is clearly related to less
improvement of VA after anti-VEGF therapy.
Trial registration: University hospital Medical Information Network (UMIN) Center UMIN000013236.
Registered 10 October, 2012.
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Background
Branch retinal vein occlusion (BRVO) was first reported
in 1896 [1]. It is known that the major risk factors for
BRVO include increasing age, systemic hypertension,
dyslipidemia, and coexisting cardiovascular diseases [2, 3].
Therefore, affected patients are also at higher risk for
future cardiovascular events. The pathomechanism lead-
ing to BRVO is not yet clear. BRVO commonly occurs at
the arteriovenous crossing. It is assumed that the diseased
artery mechanically compresses the vein. However, it has
been reported that the retinal vein seems to run deep
under the artery at the crossing in eyes with arterial over-
crossing, and the venous lumen often appears to be pre-
served, even at the arteriovenous crossing, as observed by
thin sectioning with optical coherence tomography (OCT)
in patients with acute BRVO [4]. In addition, there is an-
other possible involvement that the vein locally constricts
actively due to an altered biochemical environment, such
as locally increased endothelin-1 (ET-1) concentration.
The occlusions seem to be induced by an interaction be-
tween local and systemic factors; on the one hand, BRVOs
generally occur unilaterally, while on the other hand,
retinal venous pressure is also simultaneously increased in
the clinically unaffected contralateral eye [5, 6].
Macular edema is the major vision-threatening compli-
cation associated with BRVO, and it often causes vision
decline in patients with this disease. The congestion of the
vein can lead to local hypoxia, thereby increasing vascular
endothelial growth factor (VEGF), which in turn contrib-
utes to macular edema [7, 8]. Anti-VEGF therapy leads to
the rapid reduction of macular edema and an improve-
ment in visual function [9]. However, anti-VEGF therapy
does not improve visual acuity (VA) in every patient with
BRVO, although a regression in macular edema is present
after performing the therapy. It indicates that factors other
than VEGF are potentially involved as well.
One important candidate is endothelin [10]. ET-1 is a
potent vasoconstrictor, and it regulates the blood-retinal
barrier, stimulates the growth and migration of cells, and
regulates axoplasmic transport. It is essential for the
maintenance of cardiovascular homeostasis [11]. While
ET-1 is mainly produced by vascular endothelial cells
under physiological conditions, it can be produced by
any other cell under pathological conditions, such as
hypoxia or inflammation. The increase of VEGF points
to a local hypoxia [12]. As a result, VEGF, ET-1, or
erythropoietin and other molecules are overexpressed.
The overexpression of VEGF hints at a simultaneous
overexpression of ET-1, and most probably, both VEGF
and ET-1 are involved in the pathogenesis of macular
edema. There is a multifaceted relationship between
VEGF and ET-1. They are opponents in terms of regula-
tion of the size of vessels; while VEGF has vasorelaxing
activity, ET-1 is a potent vasoconstrictor. However, they
act synergistically on the blood-retinal barrier, and they
both weaken the barrier. In addition, a stimulatory inter-
action exists between VEGF and ET-1, affecting gene
expression and secretion in vascular cells. Therefore, re-
ducing VEGF normally also reduces the concentration of
ET-1 and vice versa.
In this prospective study, we investigated whether an
anti-VEGF therapy could influence the concentration of
ET-1 which had never been measured before and after
anti-VEGF therapy and, if so, whether changes in the
ET-1 levels are somehow related to the recovery of VA
in patients with BRVO-related macular edema. With this
hypothesis, we collected consecutive patients with acute
BRVO-related macular edema prospectively and mea-
sured their plasma ET-1 levels before and after injecting
intravitreal bevacizumab (IVB), which has the longest
serum half-life among the current available anti-VEGF
drugs [13].
Methods
This prospective study was approved by the Institutional
Review Board (IRB) at Osaka Medical College, and it
adhered to the tenets of the Declaration of Helsinki. For
this prospective study, consecutive patients with untreated
macular edema secondary to unilateral BRVO who visited
the outpatient clinic of Ophthalmology at Osaka Medical
College Hospital between November 2012 and April 2013
were enrolled.
The inclusion criteria of this study were as follows: (1)
symptomatic BRVO with macular edema; (2) a foveal
thickness greater than 250 μm, as measured by OCT at
the initial visit; and (3) macular edema secondary to
BRVO, which had never been previously treated. Diag-
nosis of BRVO was based on the findings from fundus
examinations and fluorescein angiographies. Eyes with
any coexisting ocular diseases, such as age-related macular
degeneration, diabetic retinopathy, hypertension retinop-
athy, or uveitis, were excluded.
At the initial visit, medical history, including disease du-
rations, was obtained from each patient through a medical
interview. At the initial examination, each patient under-
went comprehensive ophthalmic examinations, which
included the measurement of best-corrected VA using a
Landolt chart and fundus biomicroscopy with a non-
contact lens. Digital fundus photography, fluorescein
angiography, and OCT examination were also performed
after pupil dilation. The BRVO present in each case was
classified as ischemic if the fluorescein angiography re-
vealed more than 10 disc areas of retinal non-perfusion.
All patients were treated by injection of IVB after
obtaining their informed consent. At each visit before IVB
and 1 month after IVB, each patient underwent a com-
prehensive ophthalmologic examination, including meas-
urement of best-corrected VA, color fundus photography,
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and OCT examination; moreover, blood was collected to
measure the patient’s plasma ET-1 level. Plasma ET-1
levels were measured using an enzyme-linked immuno-
sorbent assay (ELISA) kit (Takara Bio, Shiga, Japan).
All values are presented as the mean ± standard devi-
ation. For statistical analysis, VA measured with a Landolt
chart was converted to the logarithm of the minimum
angle of resolution (logMAR). Central retinal thickness
(CRT) measured with OCT was determined as an average
retinal thickness in a 1-mm-diameter circular region at
the fovea. Paired t tests were used to evaluate changes in
the best-corrected VA (logMAR), CRT, and plasma ET-1
levels.
Results
In this study, we report on 20 eyes from 20 different pa-
tients with BRVO-related macular edema that received
treatment with IVB. No ischemic BRVO was observed in
any of the patients at the first visit, and none of the pa-
tients converted to ischemic after receiving the IVB
treatment. Table 1 shows the demographics and charac-
teristics of changes in VA, CRT, and plasma ET-1 levels
before IVB and 1 month after IVB for each patient.
Mean age was 66.1 ± 7.6, ranging from 56 to 83 years.
The patients had additional systemic diseases as follows:
16 (80 %) had hypertension, 10 (50 %) had dyslipidemia,
7 (35 %) had diabetes mellitus without retinopathy, and
1 (5 %) had collagen disease.
Before treatment, all eyes showed retinal hemorrhage
and macular edema associated with BRVO. Figure 1
shows the fundus photos and the OCT findings for a
case of macular edema secondary to BRVO before IVB
treatment and 1 month after treatment. One month after
an initial IVB injection, reduction of the macular edema
was observed in 19 (95 %) eyes. Mean CRT was signifi-
cantly decreased from 673.0 ± 327.8 μm before treatment
to 388.2 ± 155.0 μm 1 month after the initial injection
(P = 0.0007, Fig. 2). Mean VA was significantly improved
from 0.66 ± 0.37 before the treatment to 0.51 ± 0.38
1 month after treatment (P = 0.0239). The mean plasma
ET-1 level was significantly decreased after IVB from
1.272 ± 0.451 to 1.095 ± 0.316 pg/mL (P = 0.0238). Changes
in the plasma ET-1 level in the 20 patients were correlated
with changes in VA (P = 0.0025, Fig. 3).
Table 1 Characteristics of patients with macular edema associated with branch retinal vein occlusion treated by intravitreal injection
of bevacizumab
Patients Age (years) Gender General condition Before initial injection 1 month after initial injection Plasma ET-1 level (pg/mL)
before and after the treatment
VA CRT (μm) VA CRT (μm) Pre Post
1 67 M HT 0.222 577 0.046 212 1.763 0.982
2 68 F DM, HT 1 953 0.398 236 1.057 0.568
3 57 M HT, HL 0.398 692 0.155 364 1.057 0.982
4 71 M HT 0.699 577 0.824 503 1.098 1.408
5 83 F HT 1 489 0.523 391 2.121 1.388
6 61 F HT, HL 1.155 1085 0.398 523 0.965 0.848
7 70 M HT 0.398 466 0 198 1.662 1.005
8 61 F HT, HL 0.523 340 0.699 351 0.848 1.204
9 62 M DM 0.398 720 0.398 662 1.686 1.467
10 51 F HT, HL 0.523 404 0 213 1.105 1.090
11 67 M HT, HL 1.097 1093 1.097 631 1.617 1.602
12 78 M DM, HT, HL 0.523 529 0.699 488 0.568 0.613
13 69 F CD 1.523 1731 1.523 412 1.602 1.475
14 62 F DM, HL 0.523 670 0.523 567 0.940 0.832
15 56 M HL 0.398 562 0.398 540 1.456 1.041
16 68 F DM, HT 0.699 651 0.824 433 0.613 0.737
17 67 F HT, HL 0.398 612 0.398 160 1.268 1.244
18 75 M DM, HT, HL 1 442 0.699 408 2.038 1.602
19 67 M HT 0 507 0.097 210 0.762 0.864
20 61 F DM, HT 0.699 359 0.398 261 1.204 0.940
Mean ± SD 66.1 ± 7.6 0.66 ± 0.37 673.0 ± 327.8 0.51 ± 0.38 388.2 ± 155.0 1.272 ± 0.451 1.095 ± 0.316
M male, F female, DM diabetes mellitus, HT systemic hypertension, HL hyperlipidemia (dyslipidemia), CD collagen disease, VA visual acuity in logarithm of the
minimum angle of resolution (logMAR) fashion, CRT central retinal thickness
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Of the 20 eyes, VA was improved or maintained in 15
(75 %) eyes 1 month after the IVB treatment. In these 15
patients, the plasma ET-1 level was significantly de-
creased after IVB (P = 0.0007). On the other hand, the
plasma ET-1 level was increased in all five patients who
showed slightly decreased VA after IVB. In these pa-
tients with increased ET-1 level after IVB, changes in
CRT were correlated with changes in VA (P = 0.0478,
Fig. 4). To compare changes in plasma ET-1 levels
before and after the IVB treatment in improved or main-
tained vision patients (n = 15) and the other patients
(n = 5), we calculated before-after changes of plasma
ET-1 levels (%). A significant difference in changes of
plasma ET-1 level before and after IVB was observed
between these two subgroups (P < 0.0001, unpaired t
test, Fig. 5).
Discussion
In this prospective study, a local anti-VEGF treatment
for BRVO-related macular edema was applied to the
eyes of 20 patients. One month later, CRT was signifi-
cantly reduced in 19 patients (95 %), VA was improved
or remained stable in 15 patients (75 %), and VA slightly
decreased in 5 patients (20 %). On average, the plasma
ET-1 level was significantly decreased after IVB. In
addition, the ET-1 response showed a remarkably and
statistically correlated change of VA. In patients with
increased ET-1 level after IVB, there was a correlation
between changes in CRT and VA.
It is known that a reduction of VEGF normally also
leads to a reduction in ET-1 [14], and this reduction can
be explained by the stimulatory interaction between
VEGF and ET-1; however, the increase in the plasma
ET-1 level in patients with slightly decreased VA was a
surprising finding. The mechanism of this is unclear
from our study, and we only have a hypothetical explan-
ation for this result. Under hypoxia, nature produces
VEGF in an attempt to improve the oxygen supply; thus,
it is feasible that, in some cases, the reduction of the
VEGF level, while also reducing macular edema by
improving the blood-retinal barrier, can further increase
local hypoxia. This might also impede improved VA or
stimulate the production of ET-1. This stimulation may
overcome the inhibitory effect of the VEGF drop. Here,
we would like to emphasize, again, that what is going on
locally is obviously important. Nevertheless, the systemic
Fig. 1 A case of 68-year-old female, BRVO with macular edema (patient 2 in Table 1). a Upper: pre-treatment; b lower: 1 month after intravitreal
injection of bevacizumab (IVB). Macular edema was dramatically decreased, and the visual acuity was improved from 2/20 to 8/20 1 month after
IVB. Plasma ET-1 level was decreased from 1.0567 to 0.568 pg/mL
Fig. 2 Changes in central retinal thickness (CRT) before and after the
treatment. Mean CRT was significantly decreased after the treatment
(P = 0.0007, paired t test)
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level of ET-1 may provide some indirect insight. The re-
active increase in the ET-1 level after treatment with the
anti-VEGF agent raises the question as to whether the
combination of an anti-VEGF therapy with an anti-ET-1
treatment could improve visual prognosis in these
patients. Primarily, the goal of the anti-VEGF therapy
results should be on the macular edema, not on the VA,
because the VA results are dependent on many other
factors as well. In experimental retinal vein occlusion,
ET-1 blockers were found to improve retinal circulation
[15, 16]. In patients with retinal vein occlusion, calcium
channel blockers for systemic hypertension were found
to reduce retinal venous pressure [17, 18]. This partly re-
duces the effect of ET-1.
The current prospective study has some limitations: its
sample size was small and its follow-up duration was
short. Moreover, we measured the ET-1 level in plasma,
not in intraocular fluid. As under clinical conditions, a
quantification of ET-1 in the retina is not possible;
therefore, we measured the plasma ET-1 level using an
indirect approach. The plasma ET-1 level only provides
indirect and approximate information about the local
ET-1 level in the retina. Actually, Iannaccone et al. [19]
reported that plasma ET-1 levels in patients with central
retinal vein occlusion were significantly higher than
those in the normal subjects. Sin et al. [20] measured
aqueous ET-1 levels in patients with BRVO, and their
ET-1 levels in aqueous humor were more than 10 times
higher than the plasma ET-1 levels in our data. These
results indicate the possibility that the vascular endothe-
lial cells—and potentially any other cells in the eye—
could produce ET-1 under pathological conditions. In
Fig. 3 A regression line of changes in ET-1 and VA. Before-after change of plasma ET-1 was calculated as follows: (ET-1 level after IVB− ET-1 level before
IVB)/ET-1 level before IVB × 100 (%). There was a correlation between changes in ET-1 level and VA before and after IVA (r = 0.638, P = 0.0025)
Fig. 4 A regression line of changes in CRT and VA in five patients with increased ET-1 after IVB. Before-after change of CRT was calculated as
(CRT after IVB − CRT before IVB)/ET-1 level before IVB × 100 (%). There was a correlation between changes in CRT and VA (r = 0.885, P = 0.0478)
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addition, in their paper about plasma ET-1 levels before
and after systemic treatment of bevacizumab for patients
with metastatic colorectal cancer, Dirican et al. [21]
found a significant decrease in serum ET-1 levels
after treatment with bevacizumab. The effects on the
retinal vasculature might be somewhat varied; how-
ever, anti-VEGF therapy influences ET-1. In this pro-
spective study, we indicated that ET-1 is possibly
involved in the pathogenesis of BRVO, and some
BRVO patients whose VA was not improved after IVB
showed increased plasma ET-1 levels even though in-
traocular VEGF was suppressed by anti-VEGF therapy. If
we saw a patient with BRVO-related macular edema
whose ET-1 level was not decreased after an initial injec-
tion of anti-VEGF agent, we could consider the additional
injection.
Conclusions
In conclusion, a local anti-VEGF therapy for macular
edema in patients with BRVO led to an increase in the
plasma ET-1 level in some patients without visual im-
provement. The causal relationship and the therapeutic
consequences are not yet clear. However, ET-1 sup-
pressed by anti-VEGF therapy is thought to be import-
ant for patients with BRVO-related macular edema, and
this treatment approach could be used to improve their
vision. The question remains open in how far is the
connection between the ocular VEGF production, the
influence of anti-VEGF therapy, and the plasma ET-1
concentration in the decrease of the CRT and VA im-
provement in patients with BRVO.
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